Impact of Intraoperative Blood Pressure Management and Dexamethasone on Patient's Outcomes After Lung Cancer Surgery: A 2 × 2 Factorial Randomized Controlled Trial

What this Trial Is About

Researchers are investigating how managing blood pressure during surgery and the use of dexamethasone may influence early and long-term outcomes in patients undergoing surgery for non-small cell lung cancer (NSCLC). Surgery is the main treatment for NSCLC, but complications after surgery remain high and long-term survival is challenging. This study explores if avoiding low blood pressure during surgery and giving dexamethasone can reduce complications and improve survival. The trial compares four groups: routine blood pressure management with placebo, routine blood pressure management with dexamethasone, targeted blood pressure management within ±10% of baseline with placebo, and targeted blood pressure management with dexamethasone. Dexamethasone is given before anesthesia induction, and blood pressure is either managed routinely or tightly controlled throughout surgery. The study uses a 2 × 2 factorial randomized design to assess these interventions. Participants will be monitored for organ injury and complications within 5 days after surgery and followed for up to 5 years to assess overall survival and cancer-related outcomes. Researchers will collect data on intensive care unit admissions, mechanical ventilation duration, hospital stay length, and mortality rates. This comprehensive follow-up aims to evaluate both short-term safety and long-term survival benefits associated with the study interventions.

Intraoperative Blood Pressure Management and Dexamethasone in Lung Cancer Surgery